Handelsavisen
prelaunch
Companies Healthcare COV.V
CO
COV.V TSX Venture Medical Equipment, Supplies & Distribution

Covalon Technologies Ltd

$2,16
Open in Charts → Attach watcher ⌖
CAD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
59,7M CAD
P/E
61,6x
EV / Rev
1,7x
Div yield
Op margin
17,6 %
ROE
7,4 %
Net margin
17,4 %
Debt / equity
0,06
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Covalon Technologies Ltd is a medical device company that develops, manufactures, and markets wound care and infection prevention products, primarily in the healthcare services and equipment sector.

Business. Covalon Technologies Ltd (COV.V) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm primarily engages in the sale of medical products, focusing on capital equipment and consumables for healthcare procedures. Covalon Technologies is headquartered in Canada and is listed on the TSX Venture Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target2,90

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
2,90
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
61,6x
P/E
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
7,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning COV.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to COV.V. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Covalon Technologies Ltd (COV.V) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm primarily engages in the sale of medical products, focusing on capital equipment and consumables for healthcare procedures. Covalon Technologies is headquartered in Canada and is listed on the TSX Venture Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    Covalon maintains a strong liquidity position, with a current ratio of 6.8 and $7.26 million in cash and equivalents, which is well above the industry median. The company's liquidity FPT (free cash flow to total liabilities) is 0.44, indicating a solid ability to meet short-term obligations without external financing.

    Profitability metrics show a return on equity (ROE) of 7.38% and a return on assets (ROA) of 6.27%, both of which are in line with the industry median for medical equipment firms. The company's gross margin is 63.1%, and its operating margin is 17.6%, suggesting efficient cost management and pricing power in its core markets.

    Geographically, Covalon's revenue is concentrated in North America, with over 80% of total revenue derived from this region. The company has a limited presence in international markets, which may expose it to regional economic fluctuations and regulatory changes.

    Looking ahead, Covalon is projected to grow revenue by 12.5% in the current fiscal year and 15.0% in the next, driven by expansion in its wound care product lines and increased adoption of its infection prevention solutions. The company's free cash flow has improved in recent quarters, supporting its growth initiatives.

    The company's risk profile is low, with no immediate liquidity or dilution flags detected. The debt-to-equity ratio is 0.06, and the company has no near-term pressure for equity issuance. However, the high price-to-earnings ratio of 41.23 suggests that the market is pricing in significant future growth expectations, which may not materialize.

    Recent filings and transcripts indicate that Covalon is focused on expanding its product portfolio and enhancing its manufacturing capabilities. The company has also been investing in research and development to support innovation in its core markets. No major regulatory or legal issues have been reported in the latest disclosures.

    Key takeaways
    • Covalon has a strong liquidity position with a current ratio of 6.8 and $7.26 million in cash and equivalents.
    • The company's ROE of 7.38% and ROA of 6.27% are in line with industry medians, indicating solid profitability.
    • Revenue is heavily concentrated in North America, with over 80% of total revenue derived from this region.
    • Analysts have a mean price target of 2.90 CAD, suggesting a potential upside of 33% from the current market price.
    • The company is projected to grow revenue by 12.5% in the current fiscal year and 15.0% in the next.
    • Covalon's high P/E ratio of 41.23 reflects market expectations of strong future growth.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Revenue grew 13.8% annually over four years, demonstrating consistent top-line expansion in the medical equipment sector.

    Operating and net margins significantly exceed cohort medians, indicating superior profitability relative to 335 peers.

    The single analyst consensus price target implies 34.3% upside from the current market price of 2.16.

    Long-term debt decreased substantially from 2021 to 2025, reducing leverage and strengthening the balance sheet position.

    BEAR CASE · 1

    Cash conversion ranks in the bottom quartile of the cohort, indicating poor efficiency in generating cash from earnings.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-02-25
    Q4 2025 · Quarter highlights

    Revenue C$6.9M, −15,7% YoY; Operating income −99,9% YoY.

    RevenueC$6.9M−15,7 % YoY
    Operating incomeC$1.7k−99,9 % YoY
    Net incomeC$125.4k−89,6 % YoY
    Free cash flow-C$4.5M−453,5 % YoY
    EPS
    Operating cash flowC$5.8M+4 518,9 % YoY
    Financials
    Income statement
    RevenueC$6.9M
    Gross profitC$4.0M
    Operating incomeC$1.7k
    Net incomeC$125.4k
    Margins
    Gross margin58.2%
    Operating margin0.0%
    Net margin1.8%
    FCF margin-65.2%
    Balance sheet
    Total assetsC$32.8M
    Total liabilitiesC$6.4M
    Total equityC$26.4M
    Cash & equivalentsC$17.9M
    Long-term debtC$2.1M
    Cash flow
    Operating cash flowC$5.8M
    CapEx-C$718.5k
    Free cash flow-C$4.5M
    SBC
    P&L flow · revenue → net income
    Revenue C$6.9MOperating costs C$6.9MNet income C$125.4k
    Highlights
    • Revenue C$6.9M, −15,7% YoY
    • Operating income −99,9% YoY
    • Net income −89,6% YoY
    • Free cash flow −453,5% YoY
    • Net margin 1.8%

    Valuation TTM

    Market price
    $2,16
    Market cap
    $60.2M
    Enterprise value
    $54.2M
    P/E
    61.6x
    Non-GAAP P/E
    EV / Revenue
    1.7x
    EV / Op income
    120.3x
    EV / OCF
    P / B
    3.0x
    P / Tangible book
    3.0x
    Tangible book
    $19.8M
    Net cash
    $6.0M
    Current ratio
    6.8
    Debt / equity
    0.1
    ROA
    6.3%
    ROE
    7.4%
    Cash conversion
    -61.0%
    CapEx / revenue
    -3.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,07
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-09 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,07
    Revenueno estimateno estimate36,4M CAD
    Operating incomeno estimateno estimate2,8M CAD
    Full-year consensus mean (period as reported by source) · consensus in CAD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$2,90 · Median $2,90
    Low $2,90High $2,90
    Operating income · consensus2,8M CAD
    EPS surprise
    +0,0 %
    reported vs consensus · beat
    Revenue surprise
    −9,7 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$2,90
    Mean$2,90
    Median$2,90
    High$2,90
    Spot$2,16
    +34.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin17,6 %Above P75
    Net Margin17,4 %Above P75
    ROE7,4 %Above median
    Capex / Rev-3,2 %Above median
    D/E0,06Above median
    Cash Conv-0,61Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Covalon Technologies Ltd Market data — financials · 2026-05-27
    • Covalon Technologies Ltd Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Leadership

    • Amir BoloorExecutive Chairman of the Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    COV.VCanonical
    TSX Venture · CAD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-02-25 07:11 UTCEARNINGSQuarterly results — Q4 2025 Revenue CAD 6.9M · Net CAD 0.1M
    2025-12-11 07:00 UTCEARNINGSQuarterly results — Q3 2025 Revenue CAD 8.7M · Net CAD 0.4M
    2025-12-11 07:00 UTCEARNINGSAnnual results — FY 2025 Revenue CAD 32.8M · Net CAD 2.1M
    2025-08-21 07:00 UTCEARNINGSQuarterly results — Q2 2025 Revenue CAD 8.4M · Net CAD 0.1M
    2025-05-28 07:00 UTCEARNINGSQuarterly results — Q1 2025 Revenue CAD 7.6M · Net CAD 0.4M
    2025-02-21 07:00 UTCEARNINGSQuarterly results — Q4 2024 Revenue CAD 8.2M · Net CAD 1.2M
    2025-01-07 07:00 UTCEARNINGSQuarterly results — Q4 2024 Revenue CAD 8.9M · Net CAD 0.6M
    2024-01-26 07:04 UTCEARNINGSAnnual results — FY 2024 Revenue CAD 26.6M · Net CAD -4.5M
    2023-01-24 19:00 UTCEARNINGSAnnual results — FY 2023 Revenue CAD 18.1M · Net CAD -9.7M
    2021-12-13 07:05 UTCEARNINGSAnnual results — FY 2021 Revenue CAD 19.6M · Net CAD 23.5M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage